Responses
Research ethics
Gene therapy for children with cystic fibrosis—who has the right to choose?
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 18 May 2017
- Published on: 18 May 2017Missing pieces of the puzzle?Show More
Dear Editor,
Combining children and gene therapy has the potential to precipitate quite an ethically volatile mix. Consent may be impossible to obtain from a child. Yet, if we require valid consent from all research subjects, then will there not be large groups of people, children included, in need of the benefits of research who will never get them? Thus we arrive at the conclusion that through any number...
Conflict of Interest:
None declared.
Other content recommended for you
- Cystic fibrosis
- Gene therapy in cystic fibrosis
- Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation
- A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
- Recent developments and current status of gene therapy using viral vectors in the United Kingdom
- Science, medicine, and the future: Gene therapy
- Delivery of genes into the CF airway
- Gene therapy: targeting the myocardium
- Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
- Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis